top of page
tenant6

Exciting Two Weeks in Singapore and Australia

Actualizado: 14 nov

From September 30th to October 11th, our CEO and founder, Vicente Copoví, along with our CTO and co-founder, Carlos Porras, participated in the annual ICEX and Medtech Actuator program in Singapore and Australia, where we were honored to be recognized as one of Spain’s leading healthcare companies.

The two weeks provided an immersive experience within the Singaporean and Australian ecosystems, with meetings involving investors, embassies, hospitals, and distribution companies in both countries. All of this was made possible thanks to the support of ICEX and Medtech Actuator, who are committed to fostering technology-driven companies in healthcare and beyond.



The program featured presentations to investors in both Australia and Singapore, where our company demonstrated the capabilities of our sensor.

By the end of the program, we had held over 35 meetings, many of which have since progressed into ongoing discussions with hospitals, universities, and investors to continue advancing our initiatives.



For Monitoring Life, this opportunity not only validates our work but also demonstrates that we are ready to drive meaningful change in the healthcare sector. With Sensocor, our innovative sensor, we are prepared to revolutionize cardiac monitoring for patients diagnosed with heart failure.



Our company made a strong impact in meetings and exchanges with other companies, as we presented a highly professional team ready to deliver a global solution for patient care.

Monitoring Life has been developing and implementing this technology for over four years. The past year, in particular, has been one of rapid progress, enabling us to address key questions that arose along the way and provide the solutions needed.


Looking ahead to 2025, we anticipate a productive year with significant milestones, such as obtaining CE marking and completing clinical validation, which will remain our focus throughout the year.

2 visualizaciones0 comentarios

Comments


bottom of page